Combination MAD Trials: Sionna plans to initiate combination MAD trials in the second half of 2025, evaluating dual ...

It develops nucleotide-binding domain 1 (NBD1) stabilizers that normalize CFTR function for CF patients; Galicaftor (SION-2222) and SION-2851; SION-109, an ICL4-directed CFTR corrector ...

an intracellular loop 4 (ICL4)-directed CFTR corrector, in healthy subjects. Topline data are expected in mid-2026. Complementary Modulators Successful Completion of Phase 1 Trial for SION-109 ...

SION-109, which targets NBD1’s interface with the CFTR intracellular loop 4 (ICL4) region, has completed Phase 1 testing in healthy volunteers. Sionna said results showed this molecule was well ...

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline ...